Prof. Dr. Erdinç Nayır

• Neoplasms 7 publications
  Source: OpenAlex / PubMed MeSHView publications
• Breast Neoplasms 2 publications
• Carcinoma, Renal Cell 2 publications
• Kidney Neoplasms 2 publications
• Lung Neoplasms 2 publications
• Colorectal Neoplasms 2 publications

Medical areas of interest stated by the doctor on the institution profile. Source: medicalpark.com.tr.

Education

• 19972003: Fırat Üniversitesi Tıp Fakültesi – Tıp Eğitimimedicalpark.com.tr
• 20042010: Mersin Üniversitesi Tıp Fakültesi – İç Hastalıkları Uzmanlığımedicalpark.com.tr
• 20112014: Mersin Üniversitesi Tıp Fakültesi – Tıbbi Onkoloji Uzmanlığımedicalpark.com.tr

• SpecialtyMedical Oncologymedicalpark.com.trFrom source
• Department name at the sourceMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trFrom source
• InstitutionMedical Park Mersinmedicalpark.com.trFrom source
• Area of workNeoplasmsExtracted from 7 publications · Model version —From source
• Publications72 publicationsOpenAlexFrom source
• ORCID0000-0003-2348-7803ORCIDFrom source
• Last synchronised4 November 2026 20:27https://www.medicalpark.com.tr/hekimler/erdinc-nayirmedicalpark.com.tr

1. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

   Journal of Immunotherapy, 2026

   DOI 10.1097/cji.0000000000000610 PMID 42267536 Source: OpenAlex

2. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

   Journal of Clinical Medicine, 2026

   DOI 10.3390/jcm15041657 PMID 41753346 2 citations (Europe PMC) Open-access full textSource: OpenAlex

3. Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group

   Frontiers in Oncology, 2026

   DOI 10.3389/fonc.2026.1756315 PMID 42482752 1 citation (OpenAlex) Open-access full textSource: OpenAlex

4. The psychosocial status of children who have a parent with cancer.

   Journal of Clinical Oncology, 2026

   DOI 10.1200/jco.2026.44.16_suppl.12083 Open-access full textSource: OpenAlex

5. The Silent Impact of Parental Cancer on Children’s Psychosocial Well-Being

   Research Square, 2026

   DOI 10.21203/rs.3.rs-10467108/v1 Open-access full textSource: OpenAlex

6. Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study

   Scientific Reports, 2025

   DOI 10.1038/s41598-025-19899-3 PMID 41102268 Open-access full textSource: OpenAlex

7. Prognostic Significance of the Combined Albumin-To-Alkaline Phosphatase Ratio (AAPR) and Haemoglobin–Albumin–Lymphocyte–Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy: A New Prognostic Combined Risk Scoring

   Journal of Clinical Medicine, 2025

   DOI 10.3390/jcm14051742 PMID 40095849 5 citations (OpenAlex) Open-access full textSource: OpenAlex

8. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

   BMC Cancer, 2023

   DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 citations (Europe PMC) Open-access full textSource: OpenAlex

9. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

   Neoplasma, 2023

   DOI 10.4149/neo_2022_221004n984 PMID 36620878 Open-access full textSource: OpenAlex

10. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group ( TOG ) study

    Cancer Medicine, 2023

    DOI 10.1002/cam4.6869 PMID 38140782 1 citation (Europe PMC) Open-access full textSource: OpenAlex